Clinical studies of Norpace (Part IX).
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D004206:Disopyramide / Q000009:adverse effects / Q000627:therapeutic use*; D003875:Drug Eruptions; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D009230:Myxedema / Q000150:complications / Q000188:drug therapy; D011696:Purpura, Thrombocytopenic / Q000139:chemically induced; D011725:Pyridines / Q000627:therapeutic use*; D011802:Quinidine / Q000009:adverse effects / Q000627:therapeutic use; D013610:Tachycardia / Q000209:etiology
D000889:Anti-Arrhythmia Agents; D011725:Pyridines; D004206:Disopyramide; D011802:Quinidine